Journal of Clinical Oncology
Articles in this Issue
Treatment patterns and clinical outcomes in patients with triple-negative breast cancer (TNBC) and residual disease (RD) after neoadjuvant chemoimmunotherapy.
e12678 Background: Evidence on the treatment and prognosis of patients with TNBC and RD after neoadjuvant chemoimmunothera...
Differentiation and stage as independent predictors of survival in laryngeal neuroendocrine carcinoma: A SEER analysis.
e18149 Background: Laryngeal neuroendocrine carcinoma (LNEC) is rare and biologically heterogeneous. The independent progn...
Analysis of spatial atlas of ADC targets in immunotherapy-treated NSCLC to link compartment-specific target expression with tumor immune contexture, clinical outcome, and on-treatment remodeling.
3004 Background: The spatial distribution, co-expression patterns, immune contexture associations, and on-treatment evolut...
Cancer burden among adults with type 2 diabetes mellitus in the United States, 1999-2023.
e16480 Background: Type 2 Diabetes mellitus (T2DM) is associated with an increased risk of several cancers due to shared r...
A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).
TPS9597 Background: Melanoma is the fifth most common cancer, with over 100,000 new cases and 8000 related deaths projecte...
Real-world cost effectiveness of androgen receptor pathway inhibitors for metastatic hormone sensitive prostate cancer: An economic evaluation utilizing data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN).
11164 Background: Several therapies are approved for metastatic hormone sensitive prostate cancer (mHSPC), with differing...
Low-density lipoprotein receptor–related protein 1 overexpression as an identifier of brain metastasis and survival for patients with lung cancer.
2029 Background: Brain metastasis (BM) is a major cause of mortality in lung cancer. Low-density lipoprotein receptor–rela...
Natural history of weight changes in pancreatic cancer: A longitudinal analysis.
e24063 Background: Unintentional weight loss is common in people with pancreatic cancer and predicts poor outcomes. This s...
Association of dynamic changes in tumor markers with overall survival in patients with mucinous appendiceal adenocarcinoma.
e16477 Background: Mucinous appendiceal adenocarcinoma (MAA) is the most common subtype of AA, but it is difficult to accu...
Impact of Ori-TTV particles on in vivo CAR-T cell engineering for the treatment of hematologic malignancies.
6558 Background: CAR-T cell therapy has revolutionized hematological malignancy treatment, yet traditional autologous ther...
Pre-operative intratumoral toll-like receptor 9 (TLR9) agonist vidutolimod (Vidu) and stereotactic body radiation therapy (SBRT) in early triple-negative breast cancer (eTNBC): Randomized phase 2 CyberImmunoBreast trial.
e12635 Background: Vidu is a virus-like particle encapsulating a TLR9 agonist, CpG-A, promoting Th1-based innate and adapt...
Limb compression therapy and chemotherapy-induced peripheral neuropathy in women with gynecologic cancers: A prospective self-controlled study (NEURO-GLOVE Trial)—Updated long-term analysis.
5545 Background: No established strategy prevents taxane-induced CIPN. We evaluated if dual-site mechanical compression re...
Treatment-free survival (TFS) in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV)–based therapy.
4576 Background: EV as monotherapy or with pembrolizumab (EVP) has shown robust efficacy in patients with aUC. Despite lac...
Final results of a single-arm, open-label, multicenter phase 2 study of the radiopharmaceutical [ <sup>177</sup> Lu]Lu-DOTA-TATE and [ <sup>68</sup> Ga]Ga-DOTA-TATE in adults with advanced intracranial meningioma.
2090 Background: A subset of meningiomas has an aggressive clinical course requiring multimodal therapies. Yet, treatment...
Dying tumor cells as a driver of tumor repopulation after insufficient thermal ablation of papillary thyroid carcinoma.
e18046 Background: Although high-quality clinical evidence remains limited, the use of thermal ablation for papillary thyr...
Two-dimensional mathematical modeling of tumor invasion using the generalized integral transform technique: Role of haptotaxis in spatial tumor-ECM dynamics.
e15005 Background: Tumor invasion is a spatially heterogeneous and multiscale process driven by interactions between cance...
Early-phase operational readiness gaps in oncology cell and gene therapy trials and implications for scalable trial infrastructure.
11067 Background: First-in-human (FIH) and Phase 1 oncology cell and gene therapy (CGT) trials have highlighted that opera...
Real-world outcomes in triple negative breast cancer (TNBC) in patients with residual disease after neoadjuvant therapy (NEOCAPE).
e12680 Background: Although adjuvant capecitabine may improve outcomes among patients with residual triple-negative breast...
Final results of a phase II study of utidelone capsule, the first solid oral microtubule stabilizer, in metastatic breast cancer patients.
1105 Background: Attempts to develop oral microtubule inhibitors have not made significant progress in decades. Utidelone...
SIGNAL-ER-101: Signatera-guided CDK4/6 inhibitor therapy in breast cancer.
TPS648 Background: The monarchE and NATALEE trials showed that the addition of a CDK4/6 inhibitor (CDK4/6i; abemaciclib or...
Information needs of breast cancer patients in a Brazilian capital city.
e13636 Background: Breast cancer is one of the most common cancers among women worldwide and in Brazil, influenced by gene...
Impact of a centralized APP-led peer-to-peer program on patient access, provider burden, and institutional revenue.
1549 Background: Prior authorization (PA) and peer-to-peer (P2P) requirements impose a significant administrative burden o...
Effect of on-treatment dose adjustments on the efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.
4565 Background: EVP is the preferred 1 st -line regimen for patients (pts) with a...
DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial.
3000 Background: DXC006 is an antibody-drug conjugate of a humanized anti-CD56 antibody linked to the topoisomeras...
Mental health and malignancy: Real-world associations between early-onset hormone-related cancers and mental illness.
11173 Background: Although progress has been made in reducing overall cancer incidence, early-onset cancers have continued...